Spyre Therapeutics Inc. stocks have been trading up by 13.11 percent following highly positive sentiment around its latest therapeutic developments.
Click Here for a Millionaire's POV on Trading SYRE
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Deutsche Bank hiked its price target on Spyre Therapeutics to $115 after rival Abivax reported a malignancy safety signal in a Phase 3 ulcerative colitis trial.
- Part A of the Phase 2 SKYLINE trial for SPY002 in ulcerative colitis hit its primary endpoint with strong remission and endoscopic improvement plus class-consistent safety.
- Wedbush lifted its SYRE target to $100, with the stock recently trading in the low $80s while Street consensus sits near $96 and rated Buy.
- BTIG raised its Spyre Therapeutics target to $112, boosting modeled success odds across the TL1A pipeline and lowering its discount rate.
- Full enrollment of the Phase 2 SKYWAY basket trial for SPY072 keeps six rheumatology readouts on track for 2026, broadening SYRE’s catalyst calendar.
Live Update At 14:02:42 EDT: On Monday, June 22, 2026 Spyre Therapeutics Inc. stock [NASDAQ: SYRE] is trending up by 13.11%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Spyre Therapeutics, trading under ticker SYRE, has been acting like a momentum biotech name with real catalysts behind it. Over the last few weeks, SYRE has pushed from the low $70s to a recent close near $99.92, a sharp trend higher that tells you traders are aggressively repricing the story after the SPY002 data.
The daily chart shows a steady staircase: higher lows from roughly $70–$73 up through the mid‑$80s, then a breakout toward $100. Intraday action on the most recent session was tight and controlled; SYRE spent most of the afternoon grinding between $97 and just above $100, with no heavy flushes. That kind of orderly consolidation near highs often signals strong hands in control rather than fast-money blow‑off.
More Breaking News
- BTQ Stock Slides As Momentum Traders Watch Key Support
- PENG Stock Wavers As Penguin Solutions Loses CFO To Trade Desk
- KMRK Stock Pulls Back As Volatility Grips Penny Tech Name
- CBRG Stock Whipsaws As Short-Term Momentum Traders Circle
Under the hood, SYRE is classic development‑stage biotech. The company posted roughly -$69.0M in quarterly net loss and burned about -$57.4M in operating cash flow, but it ended the period with about $97.2M in cash and $741.5M including short‑term investments. Current and quick ratios near 9 show Spyre is well capitalized for now, with no reported debt. Returns on equity and assets are deeply negative, which is normal at this stage. For traders, that means the stock trades on data, sentiment, and cash runway — not earnings.
Why Traders Are Watching SYRE Right Now
SYRE is front and center on biotech screens because the company just did what the market cares about most: it delivered clean, positive clinical data in a hot mechanism. Spyre Therapeutics reported that Part A of its Phase 2 SKYLINE trial in ulcerative colitis met the primary endpoint for SPY002. The trial showed a statistically significant drop in RHI score plus high clinical remission and endoscopic improvement, with a safety profile that lines up with the TL1A class. That gives traders real proof-of-concept, not just a slide deck.
The Street responded fast. Wedbush raised its SYRE target from $80 to $100 and kept an Outperform rating after those first efficacy data. BTIG followed by moving its target from $98 to $112, explicitly increasing modeled probabilities of success not only for ulcerative colitis but also Crohn’s disease and rheumatoid arthritis, and even lowering its discount rate on Spyre Therapeutics. When analysts lower their discount rate, they’re basically saying the long‑term risk profile looks better than before.
Deutsche Bank then pushed its SYRE target to $115, and that call came with an extra twist: competitor Abivax reported a malignancy safety signal in Phase 3 ulcerative colitis. In a safety‑sensitive space like TL1A, a rival’s stumble can shift attention and perceived value toward Spyre Therapeutics. Put that together with a Street‑wide average target around $96 versus prior trading near $81–$82, and you have a name where sentiment and numbers are finally aligned.
On top of SPY002, Spyre has fully enrolled its Phase 2 SKYWAY basket trial for SPY072 across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. That sets up multiple 2026 readouts and expands the story beyond IBD. For momentum‑focused traders, that pipeline depth is key — it means SYRE isn’t a one‑and‑done event.
Conclusion
For active traders, SYRE checks several key boxes: strong recent uptrend, clear fundamental catalyst, and a full pipeline that can keep news flowing. The chart shows Spyre Therapeutics breaking out on volume and then consolidating just under $100, while analyst targets now stretch from $100 at Wedbush up to $115 at Deutsche Bank and $112 at BTIG. Street consensus around $96, combined with the recent run from the low $70s, tells you the market is quickly catching up to the new narrative.
Underneath the price, the story is straightforward. Spyre Therapeutics has de‑risked SPY002 in ulcerative colitis with Phase 2 Part A success, is pushing ahead in rheumatology with SPY072 fully enrolled, and holds a solid cash cushion with no debt on the balance sheet. Losses and negative returns reflect a company still deep in the build‑out phase, not a broken model. For SYRE, the real drivers will be upcoming data, conference commentary, and how the TL1A competitive field evolves after Abivax’s safety issues.
As Tim Sykes likes to say, “The market rewards preparation, not hope.” That focus on discipline lines up with another key trading principle: As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” For traders studying SYRE, that means mapping the catalyst calendar, respecting the volatility that comes with biotech, and always having a risk plan before touching a fast‑moving chart. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.